Navigation Links
Following the genomic pathways to stop the spread of cancer
Date:7/3/2012

BETHESDA, MD July 3, 2012 As the Genetics Society of America's Model Organism to Human Biology (MOHB): Cancer Genetics Meeting in Washington, D.C. drew to a close, it was clear that the mantra for drug discovery to treat cancers in the post-genomic era is pathways.

Pathways are ordered series of actions that occur as cells move from one state, through a series of intermediate states, to a final action. Because model organisms fruit flies, roundworms, yeast, zebrafish and others are related to humans, they share many of the same pathways, but in systems that are much easier to study. Focusing on pathways in model organisms can therefore reveal new drug targets that may be useful in treating human disease.

"By reading evolution's notes, we can discover what really matters in the genome," keynote speaker Eric Lander, Ph.D., founding director of the Broad Institute of Harvard and MIT and professor of biology at MIT, told a packed crowd at the MOHB: Cancer Genetics Meeting on June 19.

What matters the most in the genome of a cancer cell may be the seeds of drug resistance, the genetic changes that enable cells to evade our best drugs. Bert Vogelstein, M.D., director of the Ludwig Center at Johns Hopkins University and an investigator with the Howard Hughes Medical Institute and a keynote speaker on June 17, told participants. He called drug resistance to single agents a "fait accompli," or a done deal as a side effect of the evolution of cancer.

"About 3,000 resistant cells are present in every visible metastasis," said Dr. Vogelstein. "That's why we see resistance with all therapeutics, even when they work. And we can't get around it with single agents. Cancer treatment requires combinations of agents."

Presentations throughout the meeting offered specific examples of events in pathways involved in the progression of cancer in model organisms that shed light on how human cancer may metastasize.

  • To identify the genes behind a breast cancer's spread to the lungs, Joan Massagu, Ph.D., chair of the Cancer Biology & Genetics Program at Memorial Sloan-Kettering Cancer Center and colleagues, placed cells from the lung fluid of patients into mice, deducing a "breast cancer lung metastasis signature" and identifying several mediators of metastasis that are clinically relevant and potential drug targets.

  • Denise Montell, Ph.D., from Johns Hopkins University School of Medicine, traced the signaling pathways that developing egg cells in the Drosophila (fruit fly) ovary use to migrate as using some of the same genes that are expressed as ovarian cancer spreads.

  • David Botstein, Ph.D., and his group at Princeton University use yeast to model the evolution of cancer through serial mutations, revealing that only a few destinations for a particular type of cancer are possible. "Breast cancers can't turn into leukemias, There are limited subtypes, not just anything can happen," he explained.

  • David Q. Matus, Ph.D., a postdoctoral researcher at Duke University, discussed an in vivo model of cell invasion, a key component of cancer metastasis that occurs during the larval development of the roundworm, Caenorhabditis elegans. He showed that the invasive gonadal anchor cell needs to exit the cell cycle, (be non-dividing), in order to invade. Proliferative anchor cells fail to form "invadopodia" -- invasive feet or protrusions in the basement membrane -- suggesting that cell division and cell invasion are disparate states.

    The tumor suppressor "drivers" those genes that reduce the probability of a cell turning into a cancer cell -- are often deletions -- part of a chromosome or a sequence of DNA that is missing. But, a drug can't target proteins encoded by such sequences. The solution? Understand and interrogate pathways. "For every mutated tumor suppressor gene that inactivates a component of a pathway, another gene is indirectly activated," Dr. Vogelstein explained. We need model organisms to dissect the pathways that will underlie future combination therapies, he concluded.


    '/>"/>


  • Contact: Phyllis Edelman
    pedelman@genetics-gsa.org
    301-634-7302
    Genetics Society of America
    Source:Eurekalert

    Related medicine news :

    1. U.S. Mammography Rates Drop Following Task Force Recommendations
    2. Men and women receive different fertility advice following cancer diagnosis
    3. Risk of suicide and fatal heart attack immediately following a cancer diagnosis
    4. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
    5. Discovery explains how cellular pathways converge to regulate food intake and body weight
    6. Global Energy Assessment identifies pathways to a sustainable energy future
    7. VCU researchers identify changes in cholesterol metabolic pathways
    8. Mutant Kras drives pancreatic cancer maintenance via metabolic pathways
    9. PawnUp.com Online Pawn Shop Spreads Awareness About its Small Business Loans.
    10. Antibiotic-Resistant Gonorrhea Spreading: WHO
    11. Benefits of Widespread Statin Use Outweigh Risks: Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/7/2016)... ... , ... Students attending Envision’s summer 2017 National Youth ... experience in an emergency medical simulation, When Care is Hours Away. This dynamic ... skills that are critical success in a future career and beyond. , The ...
    (Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is a ... smoothing and tightening the skin of the face to create more youthful features. ... with very little downtime, Silhouette Instalift is a novel, minimally invasive facial procedure ...
    (Date:12/7/2016)... GA (PRWEB) , ... December 07, 2016 , ... In ... route to respond to an emergency medical call when he lost control of his ... After being extricated from his vehicle, he was transported to Atlanta Medical Center, where ...
    (Date:12/7/2016)... ... 07, 2016 , ... Levels of a protein in the blood associated with ... online in the journal Radiology. , Heart disease and brain disease exact a major ... rapidly aging population. Damage to both organs often occurs at a subclinical stage, or ...
    (Date:12/7/2016)... ... December 07, 2016 , ... ... services from offices located in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, ... coach who needs treatment for a brain tumor. , Jason Bauer and his ...
    Breaking Medicine News(10 mins):
    (Date:12/7/2016)... LONDON , Dec. 7,2016  Based ... drug delivery industry, Frost & Sullivan recognizes ... Frost & Sullivan Award for Enabling Technology ... plug the loopholes in traditional drug delivery ... and liquid microneedle-based drug delivery technologies, Memspatch ...
    (Date:12/7/2016)... 7, 2016  Lannett Company, Inc. (NYSE: LCI ) ... Markets 2016 Prescription for Success Healthcare Conference on December 14, 2016 ... New York City . In addition, the ... Guggenheim Securities 4 th Annual Boston Healthcare Conference taking place ... ...
    (Date:12/6/2016)... YORK , Dec. 6, 2016 Radioisotopes ... nucleus. Radioisotopes are produced either by using nuclear research ... in the form of alpha, beta or gamma when ... emitted are used in Nuclear medicine, specifically in medical ... provide diagnostic information about a human body,s functioning. Radiotherapy ...
    Breaking Medicine Technology: